Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLT091001 in Adults With Impaired Dark Adaptation
NCT01999764Phase 2Completed
- Sponsor
- QLT Inc.
- Start
- Nov 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zuretinol in nyctalopia, age-related macular degeneration (AMD), sponsored by QLT Inc.. Started Nov 2013; status: completed.
02
Drugs
zuretinol
03
Conditions
nyctalopiaage-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT01999764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999764.